SEC Form 4 · accession 0000899243-18-011944
Amneal Pharmaceuticals, Inc. · AMRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul Bisaro
Director
Period of report
May 4, 2018
Accepted (ET)
May 8, 2018 · 7:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001723128
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF2,F1 | $12.70 | May 4, 2018 | A | 850,000 | A | — | Mar 27, 2027 | Class A Common Stock | 850,000 | 850,000 | D |
| Stock OptionF3 | $15.01 | May 7, 2018 | A | 408,719 | A | — | May 7, 2028 | Class A Common Stock | 408,719 | 408,719 | D |
| Restricted Stock UnitsF4,F5 | — | May 7, 2018 | A | 99,933 | A | — | — | Class A Common Stock | 99,933 | 99,933 | D |
Explanation of responses
- F1The option is vested and currently exercisable.
- F2Received pursuant to the Business Combination Agreement, dated as of October 17, 2017, among Impax Laboratories, Inc. ("Impax"), Amneal Pharmaceuticals LLC, Atlas Holdings, Inc. and K2 Merger Sub Corporation in exchange for an option to purchase an equal number of shares of Impax common stock.
- F3The option vests in four equal annual installments beginning on May 07, 2019.
- F4Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- F5The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date.